BEXAGLIFLOZIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H29ClO7
Molecular Weight	464.936
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC=C(Cl)C(CC3=CC=C(OCCOC4CC4)C=C3)=C2

InChI

InChIKey=BTCRKOKVYTVOLU-SJSRKZJXSA-N

InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H29ClO7
Molecular Weight	464.936
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf|https://pubmed.ncbi.nlm.nih.gov/34292100

Bexagliflozin, sold under the brand name Brenzavvy, is a potent and selective SGLT2 inhibitor. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Brenzavvy is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The FDA approval on January 23, 2023 is based on results from a clinical program that evaluated the safety and efficacy of Brenzavvy in 23 clinical trials enrolling more than 5,000 adults with type 2 diabetes mellitus.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/glucose cotransporter 2 25 Target ID: CHEMBL3884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21215314 \| http://www.theracos.com/sglt2-inhibitors/	Inhibitor 8504		2.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://adisinsight.springer.com/drugs/800035524 https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf	Primary		Approved 8583	BRENZAVVY Approved Use BRENZAVVY is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Launch Date 2023

C_max

Value	Dose	Co-administered	Analyte	Population
692 ng × eq/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31432741	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		BEXAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2604 ng × eq × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31432741	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		BEXAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31432741	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		BEXAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	UGT2B7 456 CYP2C19 1119 CYP2C8 810 UGT1A9 423 UGT1A1 479 UGT1A4 399 UGT1A6 343 CYP1A2 1197 CYP2B6 776 UGT1A10 331

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/ \| https://pubmed.ncbi.nlm.nih.gov/31432741/	major
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	minor
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	minor
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	minor
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34372	https://www.001chemical.com/chem/search?q=DY34372
001 Chemical	DY34374	https://www.001chemical.com/chem/search?q=DY34374
1PlusChem LLC	1P008U59	https://www.1pchem.com/search?query=1P008U59
AstaTech	C71393	http://astatechinc.com/CPSResult.php?CRNO=C71393
BioSynth	J-500393	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/J-500393
BLD Pharm	BD629906	http://www.bldpharm.com/search/Search.html?keyword=BD629906
Cayman Chemical	21359	http://www.caymanchem.com/app/template/Product.vm/catalog/21359
Chem Scene	CS-5702	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5702
ChemShuttle	138999	https://www.chemshuttle.com/catalogsearch/result/?q=138999
eMolecules	43473247	https://orderbb.emolecules.com/search/#?query=43473247
eMolecules	44786206	https://orderbb.emolecules.com/search/#?query=44786206
eMolecules	89940547	https://orderbb.emolecules.com/search/#?query=89940547
KeyOrganics	AS-55919	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-55919
mcule	MCULE-8046541096	https://mcule.com/MCULE-8046541096/
mcule	MCULE-9598278085	https://mcule.com/MCULE-9598278085/
MedChem Express	HY-17604	https://www.medchemexpress.com/search.html?q=HY-17604&ft=&fa=&fp=
Molcore	MC34372	http://www.molcore.com/CatMC34372.html
Molcore	MC34374	http://www.molcore.com/CatMC34374.html
Molnova	M10426	https://www.molnova.com/en/serch-list.html?keywords=M10426
MolPort	MolPort-044-561-857	https://www.molport.com/shop/molecule-link/MolPort-044-561-857
ShangHai Biochempartner	BCP000523	http://www.biochempartner.com/search_BCP000523
TargetMol	T7217	https://www.targetmol.com/search?keyword=T7217
Toronto Research Chemicals	B336785	https://www.trc-canada.com/product-detail/?CatNum=B336785

PubMed

Title	Date	PubMed
EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.	2011 Apr	21215314

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dose: 20 mg once daily, taken in the morning, with or without food. Do not crush or chew the tablet.

Route of Administration: Oral

In Vitro Use Guide

Bexagliflozin (EGT1442) inhibited SGLT1 and SGLT2-mediated sodium-dependent AMG uptake in a dose-dependent manner. EGT1442 exhibited an IC50 of 2 nM with a 2435-fold selectivity ratio against SGLT2 compared to SGLT1.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:39:36 GMT 2025` Edited by `admin` on `Mon Mar 31 22:39:36 GMT 2025`
Record UNII	EY00JF42FV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

bexagliflozin [INN]

Preferred Name

English

BEXAGLIFLOZIN

Official Name

English

EGT0001442

Code

English

EGT1442

Code

English

Bexagliflozin [WHO-DD]

Common Name

English

THR-1442

Code

English

BRENZAVVY

Brand Name

English

EGT-1442

Code

English

EGT-0001442

Code

English

D-GLUCITOL, 1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(2-(CYCLOPROPYLOXY)ETHOXY)PHENYL)METHYL)PHENYL)-, (1S)-

Systematic Name

English

BEXAGLIFLOZIN [USAN]

Common Name

English

THR1442

Code

English

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-({4-[2-(cyclopropyloxy)ethoxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Systematic Name

English

Code System Code Type Description

PUBCHEM

25195624